Pharma Stocks
-
Natco Pharma shares surge 5% after US FDA’s tentative nod Olaparib tablets
Natco Pharma shares climbed as much as 4.5% on Monday, touching an intraday high of Rs 987.55 on the NSE,…
Read More » -
Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals’ (JAZZ) Investment Narrative?
In recent months, Jazz Pharmaceuticals has drawn fresh attention as investors reassess its sleep-disorder and oncology portfolios amid growing interest…
Read More » -
Eisai (TSE:4523) Following Leqembi Home Dosing Approval Is The Alzheimer’s Upside Already Priced In
Eisai (TSE:4523) is back in focus after fresh Alzheimer’s data and a new at-home dosing option for Leqembi. These developments…
Read More » -
Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story?
Alnylam Pharmaceuticals recently presented at the Alzheimer’s Association International Conference 2026 in London, sharing Phase 1 and Phase 2 updates…
Read More » -
Vertex Pharma stock steadies as cystic fibrosis franchise drives revenue and investors watch next da
Vertex Pharmaceuticals Inc. (ISIN US92532F1003) is best known for its cystic fibrosis therapies, and Vertex Pharma stock trades on Nasdaq…
Read More » -
ANI Pharmaceuticals (ANIP) Stock Looks Fairly Valued With Strong Returns But Mixed Earnings
ANI Pharmaceuticals has delivered a strong 139.1% return over the past 5 years, yet at around US$79.20 the valuation checks…
Read More » -
UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow
UroGen Pharma (URGN) is back in focus after the FDA cleared its Investigational New Drug application for UGN-501, allowing the…
Read More » -
Takeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervalued
Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib in…
Read More » -
Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins
Eton Pharmaceuticals has turned heads with a very large 3 year return and a fresh 52 week run, yet its…
Read More » -
Does Shionogi’s Pediatric Fetroja sNDA Shift the Bull Case For Shionogi (TSE:4507)?
Shionogi recently announced that the U.S. FDA has accepted a Supplemental New Drug Application for Fetroja (cefiderocol) to treat pediatric…
Read More »